# Chloroform associated with bone mineral density and bone mineral content in adults: a population-based cross-sectional research.

- Lin Li<sup>1</sup>, XK Liu<sup>2</sup>, Xia Zhang<sup>3</sup>, Yan Zhang<sup>3</sup>, Qing Li<sup>3</sup>, HF Geng<sup>2</sup>, Li Shi<sup>2</sup>, Ben 1
- Wang<sup>2</sup>, QQ Qiu<sup>2</sup>, TP Yu<sup>2</sup>, YQ Sang<sup>2</sup>, LY Wang<sup>2</sup>, Wei Xu<sup>2\*</sup>, Jun Liang<sup>1, 2\*</sup> 2
- <sup>1</sup>Graduate School of Bengbu Medical College, Bengbu, Anhui, China. 3
- <sup>2</sup>Department of Endocrinology, Xuzhou Central Hospital, Xuzhou Institute of Medical 4
- Sciences, Xuzhou Clinical School of Nanjing Medical University, Affiliated Hospital 5
- of Medical School of Southeast University, Jiangsu, China. 6
- <sup>3</sup>Xuzhou Medical University, Xuzhou, Jiangsu, China. 7
- **First-author**: 8
- Lin Li, email: 1621561732@gg.com 9

#### **Co-authors:** 10

- XK Liu, email: liuxuekui314@126.com 11
- Xia Zhang, email: garnele99@163.com 12
- Yan Zhang, email: zhangyan202103@126.com 13
- 14 Qing Li, email: 769798497@qq.com
- HF Geng, email: genghoufa@njmu.edu.cn 15
- Li Shi, email: shili2006 2009@126.com 16
- Ben Wang, email: wangben1210@126.com 17
- QQ Qiu, email: qqq18796249070@163.com 18
- TP Yu, email: yutianpei1188@163.com 19
- YQ Sang, email: sangyiquan86@163.com 20
- LY Wang, email: 786773733@gg.com 21
- <sup>¶</sup>These authors contributed equally to this work. 22

#### \* Correspondence: 23

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 24 Jun Liang, email: mwlj521@njmu.edu.cn
- 25 Wei Xu, email: weixu159357@njmu.edu.cn

### 26 Abstract

**Background:** According to a recent cross-sectional study, reduced Bone Mineral Density (BMD) in U.S. adults is associated with co-exposure to several Volatile Organic Compounds (VOCs), and contact with VOCs increases the risk of developing osteoporosis. However, the relationship between chloroform (an essential VOC component) and BMD remains unclear. Consequently, we aimed to explore the relationship between chloroform alone and Bone Mineral Density or Bone Mineral Content (BMD or BMC).

Methods: Herein, 2,553 individuals aged 18 and above from the National Health and Nutrition Examination Surveys (NHANES) in 2009-2010, 2013-2014, and 2017-2020, were included. We employed two independent t-tests and multi-linear regression models to statistically assess the relationship between chloroform exposure and BMD/BMC in the spine and femoral area.

**Results:** A "V"-shaped correlation between chloroform exposure and BMD/BMC 39 was observed in the unadjusted model, particularly in the Ward's triangle and femoral 40 neck as a whole. A negative correlation was specifically observed for the Ward's 41 triangle BMD/BMC and L4 BMD/BMC. On the other hand, in the adjusted model, a 42 dominantly negative correlation between the L4 BMC and chloroform exposure was 43 observed over a range of exposure levels. The subgroup analysis revealed a negative 44 correlation between chloroform concentrations and BMC in the femur and spine, 45 especially in women and the 65-80 age population. 46

47 Conclusion: Our study revealed a "V" shaped correlation between chloroform and
48 BMD/BMC of the femur and spine in U.S. adults. This finding highlights the fact that
49 prolonged exposure to chloroform may increase the risk of developing osteoporosis.

### 50 Introduction:

Osteoporosis is a frequent bone disease characterized by reduced bone volume, 51 microstructural degeneration, and fragility fractures [1]. Fragility fractures, particularly 52 in the most vulnerable areas, including the vertebrae, hip, and forearm, are one of the 53 severe complications of osteoporosis. According to reports [2,3], fragility fractures can 54 cause emotional distress, reduced quality of life, and an increased socioeconomic 55 burden. Approximately 79,000 people in the United Kingdom suffer hip fractures 56 annually, with the cost in 2010 estimated at £3.5 billion and expected to rise to £5.5 57 billion each year by 2025, implying that osteoporosis will be a significant challenge in 58 the future and its burden on the medical community must be removed [4]. According 59 to osteoporosis research, enhancing Bone Mineral Density (BMD) is closely linked to 60 61 decreasing the risk of vertebral and non-vertebral fractures [5]. Many factors, including aging, femininity, estrogen metabolism disturbances, and physical inactivity, are 62 critical in lowering BMD and have been implicated in the pathogenesis of osteoporosis 63 [6,7]. 64

People are frequently exposed to Volatile Organic Compounds (VOCs) such as chloroform, bromoform, dibromochloromethane, and dichlorobromomethane. The increased contact is due to the widespread use of disinfectants, as these VOCs are produced when disinfectants react with organic substances in water sources [8, 9, 10].

Compared to normal mice, the U.S. National Toxicology Program noted an increased 69 incidence of sternal dysplasia in bromoform-exposed mice [11]. Other studies 70 71 discovered a connection between VOC exposure and bone-healing-related chemokines, with a downregulated osteoblast chemokine CXCL12 expression after exposure to 72 benzene or its derivatives, and that CCL2 (a chemokine essential for osteoclast 73 formation) production was induced by chlorobenzene exposure [12, 13, 14]. These 74 findings imply that VOCs could impact BMD levels by affecting osteoblast activity. 75 Additionally, individual and combined VOC exposure was found to be associated with 76 77 lower BMD in U.S. adults, and Alkaline Phosphatase (ALP), Body Mass Index (BMI), Fasting Insulin (F.I.), and High-Density Lipoprotein (HDL) were shown to be 78 intermediaries in VOC and BMD co-exposure [15]. Chloroform, a significant member 79 80 of VOCs, is strongly absorbed through the pulmonary, oral, and dermal pathways and is linked with several acute and chronic illnesses, including neurological, respiratory, 81 hepatic, and renal dysfunctions, reproductive abnormalities, and digestive or urinary 82 83 malignancies [16, 17]. However, the connection between blood chloroform and 84 BMD/BMC was rarely investigated alone in past studies.

This research aimed to explore the relationship between blood chloroform and BMD/BMC using data from the National Health and Nutrition Examination Survey (NHANES). We, therefore, obtained femur BMD/BMC and spine BMD/BMC datasets published in 2009-2010, 2013-2014, and 2017-2020 from NHANES.

### 89 Materials and methods

5

### 90 Study design and participants

Herein, data from the NHANES, a cross-sectional survey of more than 5,000 91 92 respondents conducted yearly by the Center for Disease Control and Prevention's (CDC) Center for Health Statistics, was used. We specifically used NHANES data from 2009-93 2010, 2013-2014, and 2017-2020. We selected 22,333 adults (of whom 6,227 had blood 94 chloroform data) from 36,272 available subjects. Subsequently, 2637 individuals with 95 femur and spine Dual-Energy X-ray Absorptiometry (DEXA) data were selected. After 96 excluding patients with a history of osteoporosis treatment, 2553 subjects aged >18 97 98 vears were included in the final statistical analysis. Fig1 depicts the flowchart for 99 participant exclusion. (Fig1: Flowchart for Screening Research Subjects)

### 100 Variables

101 In this study, we used blood chloroform concentration as the exposure variable. Chloroform concentration in the blood was analyzed using Capillary Gas 102 Chromatography (G.C.) and Mass Spectrometry (M.S.) with Selected Ion Monitoring 103 (SIM) detection and isotope dilution. The chloroform detection limits ranged from 104 0.00148 to 0.602 ng/ml, and for lower LLOD (Lower Limit of Detection) values, an 105 interpolated LLOD value divided by the square root of 2 was used. The dependent 106 variables were the femoral and spinal Bone Mineral Density (BMD) and Bone Mineral 107 Content (BMC). In Shepherd's laboratory, Dual-Energy X-ray Absorptiometry (DXA) 108 was used to measure the spine and femur BMC, whereas the Hologic software APEX 109 v4.0 (Hologic) sector beam densitometry was used to scan and calculate the spine and 110 femur BMC and BMD. All variables included as covariates in the study are listed below: 111

112	Gender (male, female), Race/ethnicity (Mexican-American, Non-Hispanic white, Non-
113	Hispanic black, other Hispanic, other race), Household Poverty-Income Ratio (PIR by
114	poverty line: values 0 to 0.99 indicate below poverty, $\geq$ 1.00 indicate poverty or above
115	poverty)[18], Excessive alcohol consumption (>1 drink /day for women or >2 drinks
116	/day for men (in the past 12 months)), Hypertension (blood pressure $\geq$ 140/90 mmHg or
117	taking anti-hypertensive medication), Diabetes mellitus (self-reported diabetes history,
118	Fasting Blood Glucose (FPG) level $\geq$ 7.0 mmol/L, HbA1c $\geq$ 6.5% or taking anti-diabetic
119	medication), Arthritis, Cardiovascular disease (self-reported congestive heart failure,
120	coronary artery disease, heart attack or stroke history), Thyroid problems (self-reported
121	hyperthyroidism, hypothyroidism, thyroiditis), COPD(Chronic Obstructive Pulmonary
122	Disease), Smoking (self-described as having smoked $\geq 100$ cigarettes in a lifetime),
123	History of osteoporosis treatment and osteopenia (Bone Mineral Density (BMD) T-
124	score $\leq$ -2.5 in lumbar spine or femoral neck) [19]. Age, body weight, abdominal
125	circumference, and BMI were all continuous covariates in our analysis. The blood
126	chloroform, BMD, BMC, and covariance data were obtained from the NHANES
127	website.

128 Statistical analysis

129 Statistical analyses were conducted using R software (version 3.6.1), IBM SPSS

version 25(IBM, Armonk, New York, USA), and GraphPad Prism9. The mean and

- 131 Standard Deviation (S.D.) values were used for variables with continuous features,
- 132 whereas categorical variable represented frequency. The Spearman correlation test
- 133 was used to assess differences between the classification variables in the exposure

134	group. The Kruskal-Wallis test or one-way ANOVA was used to examine differences
135	in continuous variables between groups. Blood chloroform levels were grouped into
136	tertiles (tertile 1: <33%, tertile 2: 33-66%, tertile 3: >66%) and univariate and
137	multivariate linear regression models were tested to analyze the relationship between
138	the different blood chloroform categories. We adjusted the confounding variables in
139	the multi-linear regression model to investigate the correlation between blood
140	chloroform levels and BMD/BMC (femoral and spine). These included Model 1 (the
141	unprecedented model), Model 2 (for gender, age, race, and BMI adjustment), and
142	Model 3 (for gender, age, race, BMI, osteoporosis, COPD, and thyroid problems
143	adjustments, and further adjustment for arthritis, smoking and excessive drinking).
144	Regression analysis results were expressed as $\beta$ (beta) coefficients, 95% confidence
145	intervals, and statistically significant P values (P values<0.05).

## 146 **Results**

### 147 Subjects characteristics

148 This study had 2553 participants (1288 women and 1265 men). Based on the femoral and spinal DEXA data, the average age of the participants and the average chloroform 149 levels in their whole blood was 48.83 years and  $0.0171 \pm 0.0182$  ng/mL (ranging from 150 0.0021 to 0.1790 ng/mL), respectively. The weighted characteristics of these 151 participants based on the third-class classification are shown in TableS1. According to 152 the femoral and spine DEXA data, differences among groups in baseline variables such 153 as age, race, height, BMI, waist circumference, hypertension, arthritis, thyroid illnesses, 154 and smoking were statistically significant (P<0.05). 155

### 156 **Connection between chloroform and BMD**

Tables1-2 and S2 illustrate the results. Blood chloroform concentration by tertile had a statistically significant relationship with total femoral BMD (P < 0.05); femoral neck BMD (P < 0.01); rotor BMD (P < 0.05); inter-rotor BMD (P < 0.05); Ward's triangle BMD (P < 0.01); and L4 BMD (P < 0.01).

The multiple linear regression models and weighted univariate analyses are 161 detailed in Tables1-2. All regressions were conducted before adjusting for some of the 162 covariates (model 1), except for total spine BMD (β -0.0020; 95% CI -0.0051, 0.0011), 163 L1 BMD (β 0.0004; 95% CI -0.0030, 0.0039), L2 BMD (β - 0.0024; 95% CI -0.0057, 164 0.0009), and L3 BMD (β -0.0016; 95% CI -0.0048, 0.0016). A statistically significant 165 correlation existed between increased blood chloroform concentration and total femoral 166 167 BMD, femoral neck BMD, rotor BMD, inter-rotor BMD, Ward's triangle BMD, and L4 BMD (P<0.05). The L4 BMD was negatively correlated with blood chloroform 168 levels after adjusting for some covariates (model 2). After adjusting for more relevant 169 covariates simultaneously (model 3), L4 BMD decreased with rising blood chloroform 170 levels, but not at other sites. 171

		Model1	Model2	Model3
		β(95%CI) value	β(95%CI) P value	β(95%CI) P value
	Chloroform (ng/mL)			
Total femur BMD(g/cm2) *	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
rotar roman BittB(g.om2)	Q2 : 0.00875-0.01690ng/ml	0.0014(-0.0054,0.0083)0.681	0.0043(-0.0012,0.0098)0.123	2         Model3 fg(95%Cl) P value           xee         Reference           0098(0) 123         0.0047(-0.0007,0.0102)0.090           xee         -0.0029(-0.0084,0.0026)0.308           xee         -0.0029(-0.0084,0.0026)0.308           xee         -0.0029(-0.0084,0.0026)0.308           xee         -0.0029(-0.0049,0.0097)0.520           0.00140,012         -0.0664(-0.0138,0.00990,0.87           xee         Reference           0.0057(0,876         -0.0001(-0.0073,0.0051)0.871           0.0058(0,876         -0.0006(-0.0073,0.0051)0.871           0.0058(0,876         -0.0006(-0.0073,0.0051)0.871           0.0058(0,789         -0.0046(-0.013,0.0021)0.182           xee         Reference           0.0058(0,249         -0.0046(-0.013,0.0021)0.182           xee         Reference           0.0119(0,0159         0.0060(-0.0004,0.0123)0.0055           0.0026(0,250         -0.0045(-0.0109,0.012)0.164           xee         Reference           0.0124(0,409         0.0057(-0.0145,0.00300).198           xee         Reference           0.01020,055         0.0058(0.0003,0.0114)0.039           0.0035(0,239         -0.0035(0.0030,0.0140,0.039)           0.00100,055         0.0058(0.0003,0.0140,0.039)
	Q3 : 0.01700-0.17900ng/ml	-0.0082(-0.0150,-0.0014)0.019	Reference	-0.0029(-0.0084,0.0026)0.308
	Chloroform (ng/mL)			
Total femur BMC(g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
rotar femar Bine(g)	Q2 : 0.00875-0.01690ng/ml	0.0034(-0.0075,0.0144)0.542	0.0021(-0.0052,0.0094)0.574	0.0024(-0.0049,0.0097)0.520
	Q3 : 0.01700-0.17900ng/ml	-0.0142(-0.0252,-0.0033)0.011	-0.0060(-0.0133,0.0014)0.112	-0.0064(-0.0138,0.0009)0.087
	Chloroform (ng/mL)			
Eemoral neck BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
emotar neek BiviD(g/em2)	Q2 : 0.00875-0.01690ng/ml	-0.0071(-0.0148,0.0005)0.070	-0.0005(-0.0066,0.0056)0.876	-0.0001(-0.0062,0.0060)0.983
	Q3 : 0.01700-0.17900ng/ml	-0.0089(-0.0166,-0.0012)0.024	-0.0004(-0.0066,0.0057)0.889	-0.0011(-0.0073,0.0050)0.714
	Chloroform (ng/mL)			
Famoral pack PMC(g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
remotal neck BMC(g)	Q2 : 0.00875-0.01690ng/ml	-0.0055(-0.0147,0.0037)0.238	-0.0009(-0.0076,0.0058)0.789	-0.0006(-0.0073,0.0061)0.871
	Q3 : 0.01700-0.17900ng/ml	-0.0142(-0.0233,-0.0051)0.002	-0.0040(-0.0107,0.0028)0.249	-0.0046(-0.0113,0.0021)0.182
	Chloroform (ng/mL)			
Trochanter BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
rioenanier BiviD(geni2)	Q2 : 0.00875-0.01690ng/ml	0.0031(-0.0043,0.0106)0.411	0.0055(-0.0008,0.0119)0.089	0.0060(-0.0004,0.0123)0.065
	Q3 : 0.01700-0.17900ng/ml	-0.0090(-0.0164,-0.0015)0.018	-0.0037(-0.0101,0.0026)0.250	-0.0045(-0.0109,0.0019)0.164
	Chloroform (ng/mL)			
Trochanter BMC (g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
riochanter Bivic (g)	Q2 : 0.00875-0.01690ng/ml	0.0070(-0.0050,0.0189)0.253	0.0037(-0.0051,0.0124)0.409	0.0040(-0.0047,0.0127)0.371
	Q3 : 0.01700-0.17900ng/ml	-0.0116(-0.0234,0.0005)0.059	-0.0053(-0.0140,0.0035)0.239	-0.0057(-0.0145,0.0030)0.198
	Chloroform (ng/mL)			
Intertrochanter BMD(a/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
intertrotenanter BiviD(g/cin2)	Q2 : 0.00875-0.01690ng/ml	0.0032(-0.0035,0.0100)0.349	0.0054(-0.0001,0.0110)0.055	0.0058(0.0003,0.0114)0.039
	Q3 : 0.01700-0.17900ng/ml	-0.0070(-0.0138,-0.0002)0.043	-0.0016(-0.0072,0.0040)0.566	-0.0021(-0.0077,0.0034)0.445
	Chloroform (ng/mL)			
Intertrochanter BMC (a)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
internoenanter Bivice (g)	Q2 : 0.00875-0.01690ng/ml	0.0038(-0.0078,0.0154)0.521	0.0021(-0.0057,0.0099)0.596	0.0024(-0.0054,0.0102)0.547
	Q3 : 0.01700-0.17900ng/ml	-0.0151(-0.0267,-0.0036)0.010	-0.0064(-0.0143,0.0014)0.107	-0.0068(-0.0147,0.0010)0.086
	Chloroform (ng/mL)			
Wards triangle BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
(unus unungie Binib(g/enil2)	Q2 : 0.00875-0.01690ng/ml	-0.0116(-0.0241,0.0009)0.069	0.0059(-0.0037,0.0155)0.228	0.0068(-0.0027,0.0163)0.162
	Q3 : 0.01700-0.17900ng/ml	-0.0184(-0.0301,-0.0059)0.004	-0.0002(-0.0098,0.0094)0.962	-0.0017(-0.0113,0.0078)0.725
	Chloroform (ng/mL)			
Wards triangle BMC (g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
(g)	Q2 : 0.00875-0.01690ng/ml	-0.0117(-0.0253,0.0019)0.091	0.0073(-0.0032,0.0179)0.172	0.0083(-0.0022,0.0188)0.120
	Q3 : 0.01700-0.17900ng/ml	-0.0209(-0.0345,-0.0074)0.002	-0.0023(-0.0129,0.0083)0.666	-0.0040(-0.0145,0.0065)0.457

Model 1:no covariates were adjusted;Model 2:sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI were adjusted; Model 3: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI, smoking, alcohol consumption, arthritis, COPD, history of osteoporosis, thyroid problems were adjusted. \*Logarithmic conversion of all BMD/BMC data.

### 173

172

		Model1	Model2	Model3
		β(95%CI) value	β(95%CI) P value	β(95%CI) P value
	Chloroform (ng/mL)			
and an	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
otai spine BMD(g/cm2)*	Q2 : 0.00875-0.01690ng/ml	0.0018(-0.0045,0.0082)0.572	0.0023(-0.0037,0.0082)0.456	0.00241(-0.0035,0.0083)0.424
	Q3 : 0.01700-0.17900ng/ml	-0.0054(-0.0118,0.0009)0.093	-0.0049(-0.0109,0.0010)0.106	-0.0050(-0.0109,0.0010)0.100
	Chloroform (ng/mL)			
	O1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
otal spine BMC (g)	O2 : 0.00875-0.01690ng/ml	0.0036(-0.0062.0.0135)0.471	0.0027(-0.0059.0.0113)0.535	0.0029(-0.0057.0.0114)0.510
	O3 · 0.01700-0.17900ng/ml	-0.0110(-0.02080.0012)0.028	-0.0080(-0.0166.0.0006)0.068	-0.0080(-0.0165.0.0006)0.068
	Chloroform (ng/mL)			
	O1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
1 BMD(g/cm2)	O2 · 0.00875-0.01690ng/ml	0.0039(-0.0030.0.0108)0.266	0.0040(-0.0023.0.0103)0.211	0.0042(-0.0021.0.0104)0.194
	O3 : 0.01700-0.17900ng/ml	-0.0014(-0.0083.0.0055)0.695	-0.0002(-0.0066.0.0061)0.941	-0.0002(-0.0065.0.0061)0.951
	Chloroform (ng/mL)	0.0011( 0.0003,0.0035)0.055	0.0002( 0.0000,0.0001)0.511	0.0002( 0.0003,0.0001)0.551
	O1 · 0.00210-0.00874ng/ml	Reference	Reference	Reference
.1 BMC (g)	$O_2^{-1} : 0.00875 0.01690 mg/ml$	0.0083(-0.0026.0.0191)0.136	0.0053(-0.0038.0.0144)0.251	0.0054(-0.0036.0.0144)0.241
	Q2 : 0.01700 0.17900ng/ml	0.0030(-0.0138.0.0079)0.592	0.0001(.0.0092.0.0090)0.986	0.0002(-0.0089.0.0093)0.970
	Chloroform (ng/mL)	-0.0050(-0.0158,0.0077)0.572	-0.0001(-0.0072,0.0070)0.780	0.0002(-0.0003,0.0073)0.770
	O1 : 0.00210-0.00874ng/ml	Reference	Beference	Reference
2 BMD(g/cm2)	$O_2^2 : 0.00875-0.01690 \text{mg/ml}$	0.0007(-0.0060.0.0073)0.839	0.0020(-0.0042.0.0081)0.533	0.0021(-0.0040.0.0082)0.498
	Q2 0.00875-0.01090ng/ml	0.0067(-0.0000,0.0073)0.857	0.0020(-0.0042,0.0081)0.555	0.0021(-0.0040,0.0082)0.478
	Chloroform (ng/mL)	0.0002( 0.0120,0.0001)0.000	0.0015( 0.0107,0.0017)0.155	0.0010( 0.0107,0.0010)0.117
	Q1 + 0.00210-0.00874ng/ml	Pafarance	Dafaranca	Dafaranca
2 BMC (g)	Q1 0.00210-0.00874ng/ml	0.0054(.0.0048.0.0157)0.297	0.0045(-0.0042.0.0133)0.310	0.0046(-0.0041.0.0133)0.297
	Q2 : 0.01700 0.17000mg/ml	0.0118(.0.02200.0016)0.022	0.0078(.0.0166.0.0010)0.082	0.0076(-0.0041,0.0155)0.277
	Chloroform (ng/mL)	-0.0118(-0.0220,-0.0010)0.025	-0.0078(-0.0100,0.0010)0.082	-0.0070(-0.0104,0.0011)0.080
	Q1 0.00210.0.00874no/ml	Deference	Bafaranaa	Deference
3 BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	0.0012/ 0.0052.0.0077)0.710	0.0017(.0.0045.0.0070)0.505	0.0018( 0.0042 0.0070)0 566
	Q2 : 0.00875-0.01090ing/ml	0.0012(-0.0033,0.0077)0.719	0.001/(-0.0043,0.0079)0.393	0.0013(-0.0043,0.0079)0.300
	Chloraform (no/mL)	-0.0030(-0.0113,0.0013)0.130	-0.005(-0.0113;0.0011)0.105	-0.0032(-0.0113,0.0010)0.101
	Q1 . 0.00210.0.00874no/ml	Bafaranaa	Pafaranaa	Poforonoo
3 BMC (g)	Q1 : 0.00210-0.008741g/ml	0.005517(.0.0042.0.0152)0.267	0.0048(.0.0020.0.0125)0.281	0.0040(.0.0027.0.0126)0.262
	Q2 : 0.00875-0.01090iig/iii	0.003317(-0.0042,0.0133)0.207	0.0048(-0.0039,0.0133)0.281	0.0049(-0.0037,0.0130)0.203
	Q3 : 0.01700-0.17900lig/lil	-0.0110(-0.0213,-0.0019)0.020	-0.0091(-0.0178,-0.0004)0.040	-0.0092(-0.0178,-0.0005)0.058
	O1 0.00210.0.00874no/ml	Bafaranaa	Pafaranaa	Poforonoo
4 BMD(g/cm2)	Q1 : 0.00210-0.008/4hg/mi	0.0022( 0.0042 0.0088)0.404	CONTRACTOR 0 00200 527	Reference
	Q2 : 0.008/5-0.01690ng/ml	0.0023(-0.0043,0.0088)0.494	0.0020(-0.0042,0.0083)0.527	0.0022(-0.0040,0.0084)0.489
	Q5 : 0.01/00-0.1/900ng/ml	-0.0073(-0.0138,-0.0008)0.028	-0.00/8(-0.0140,-0.0015)0.015	-0.00/9(-0.0141,-0.0017)0.013
	Chloroform (ng/mL)	D 6	P. 6	D. (
4 BMC (g)	Q1 : 0.00210-0.00874ng/ml	Kelerence	Kelerence	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0015(-0.0083,0.0114)0.758	0.0004(-0.0085,0.0093)0.926	0.0006(-0.0082,0.0095)0.889
	Q3 : 0.01700-0.17900ng/ml	-0.0145(-0.0243,-0.0047)0.004	-0.0128(-0.0217,-0.0039)0.005	-0.0129(-0.0218,-0.0041)0.004

Model 1:no covariates were adjusted, Model 2:sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI were adjusted; Model 3: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI, smoking, alcohol consumption, arthritis, COPD, history of osteoporosis, thyroid problems were adjusted. \*Logarithmic conversion of all BMD/BMC data. 174

### **Connection between chloroform and BMC** 176

Detailed results are presented in Tables1-2 and S2. Weighted univariate and multiple 177

<sup>175</sup> 

linear regression analyses are illustrated in Tables 1-2. In model 1, blood chloroform 178 levels were categorized by tertile, except for rotor BMC ( $\beta$  -0.0023; 95% CI -0.0066, 179 0.0021), and L1 BMC (β -0.0004; 95% CI -0.0058, 0.0049). There was a negative 180 correlation between increased blood chloroform concentrations and BMC at several 181 sites, including total femoral BMC, femoral neck BMC, Intertrochanter BMC, Ward's 182 triangle BMC, total spine BMC, L2 BMC, L3 BMC, and L4 BMC. Additionally, 183 increased blood chloroform concentrations in the femur and spine were negatively 184 correlated with BMC (P < 0.05). The L3 BMC and L4 BMC were negatively correlated 185 186 with blood chloroform levels after adjusting for some covariates (model 2). Finally, in model 3, L3 BMC and L4 BMC decreased with increasing blood chloroform 187 concentration. 188

189

### **Subgroup** analysis

The findings of subgroup analyses adjusted for associated covariates are shown in 190 Tables3-5. According to the Multiple regression analysis in the femoral area, the 191 femoral neck BMC blood chloroform level decreased in the male gender ( $\beta$  -0.0059; 95 192 % CI -0.0115, -0.0002; P < 0.05). According to the analysis by race as a subgroup, the 193 194 femoral neck BMD/BMC in Non-Hispanic White and other Race-Including Multi-Racial subjects exhibited a negative correlation with blood chloroform concentration 195 (P < 0.05). In contrast, no meaningful correlation between blood chloroform and BMD 196 or BMC was observed in Mexican-American, Non-Hispanic Black, and Other Hispanic 197 subjects. A negative correlation between blood chloroform and femoral neck 198 BMD/BMC was revealed by the results stratified by age but only in the 65-80 years-199

#### old participants (β -0.0100; 95% CI -0.0186, -0.0014; P<0.05); (β -0.0144; 95% CI -200

#### 0.0234, -0.0054; P<0.05). 201

Table3 Association of blood chloroform with femur neck BMD/BMC, stratified by sex, race/ethnicity and age.						
	femur neckBMD (g/cm2)	β(95%CI) value	femur neck (g)	β(95%CI) value		
Subgroup analysis stratified by gender	ſ					
male	-0.0020(-0.0073,0.	0033)0.454	-0.0045(-0.	0100,0.0011)0.114		
female	-0.0046(-0.0100,0.	0008)0.094	-0.0059(-0.	0115,-0.0002)0.041		
Subgroup analysis stratified by race/e	thnicity					
Mexican American	-0.0020(-0.0098,0.	0058)0.617	-0.0041(-0.	0139,0.0058)0.416		
Other Hispanic	-0.0052(-0.0163,0.	0060)0.361	-0.0079(-0.	0215,0.0057)0.253		
Non-Hispanic White	-0.0075(-0.0135,-0.	.0015)0.015	-0.0086(-0.	0158,-0.0015)0.018		
Non-Hispanic Black	-0.0086(-0.0178,0.0	0006)0.0664	-0.0104(-0.	0211,0.0003)0.056		
Other Race—Including Multi-Racial	-0.0119(-0.0242,0.	0003)0.056	-0.0171(-0.	0324,-0.0018)0.028		
Subgroup analysis stratified by age						
18-45	0.0034(-0.0010,0.0	0078)0.126	0.0018(-0.	0031,0.0066)0.478		
45-65	0.0016(-0.0032,0.0	0064)0.517	-0.0006(-0.	0058,0.0047)0.832		
65-80	-0.0100(-0.0186,-0	.0014)0.022	-0.0144(-0.	0234,-0.0054)0.002		

BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

203

202

-1 a Diver (ANNOLIALIVE VEDDIVED A DIVED VIVED VILLE WALLS IN DEVELOPED A MEALED AN A A LANDA AND A DIVED A DIVEDA DIVED A DIVED A DIVED A DIVED A DIVEDA DIVE	Table4 Association of blood	l chloroform with wards triang	de BMD/BMC, stratified by sex	, race/ethnicity and age.
---	-----------------------------	--------------------------------	-------------------------------	---------------------------

	Wards triangle BMD	(g/cm2)	β(95%CI) value	Wards triangleBMC (g)	β(95%CI) value
Subgroup analysis stratified by gender					
male	-0.0020(	-0.0110,0.	0069)0.658	-0.0023(-0.0118,0	0.0072)0.634
female	-0.0118(-	-0.0204,-0	.0032)0.007	-0.0144(-0.0239,-	0.0049)0.003
Subgroup analysis stratified by race/ethr	nicity				
Mexican American	-0.0024(	-0.0148,0.	0100)0.703	-0.0036(-0.0172,0	0.0100)0.605
Other Hispanic	-0.0068(	-0.0244,0.	0109)0.451	-0.0090(-0.0281,0	0.0102)0.358
Non-Hispanic White	-0.0124(-	-0.0224,-0	.0024)0.015	-0.0136(-0.0244,-	0.0027)0.015
Non-Hispanic Black	-0.0133(	-0.0286,0.	0021)0.091	-0.0153(-0.0318,0	0.0012)0.070
Other Race-Including Multi-Racial	-0.0103(	-0.0293,0.	0087)0.289	-0.0118(-0.0324,0	.0089)0.2639
Subgroup analysis stratified by age					
18-45	0.0037(-	-0.0025,0.	0099)0.241	0.0018(-0.0052,0	.0088)0.616
45-65	0.0052(-	-0.0023,0.	0128)0.175	0.0049(-0.0034,0	.0131)0.251
65-80	-0.0065(	-0.0211,0.	0081)0.381	-0.0060(-0.0216,0	0.0095)0.447

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

204 205

### Table5 Association of blood chloroform with L4 BMD/BMC, stratified by sex, race/ethnicity and age.

	L4BMD (g/cm2)	β(95%CI) value	L4BMC (g)	β(95%CI) value
Subgroup analysis stratified by gender	·= ·			• • •
male	-0.0012(-0.00	57,0.0033)0.600	-0.0034(-0.00	98,0.0030)0.297
female	-0.0044(-0.00	90,0.0002)0.060	-0.009(-0.014	19,-0.0022)0.009
Subgroup analysis stratified by race/ethn	icity			
Mexican American	-0.0055(-0.01	25,0.0015)0.124	-0.0107(-0.02	17,0.0002)0.054
Other Hispanic	-0.0028(-0.01	24,0.0067)0.560	-0.0058(-0.02	04,0.0088)0.437
Non-Hispanic White	-0.0044(-0.00	93,0.0005)0.082	-0.0078(-0.01	52,-0.0005)0.037
Non-Hispanic Black	-0.0066(-0.01	42,0.0011)0.095	-0.0109(-0.02	23,0.0004)0.059
Other Race—Including Multi-Racial	-0.0057(-0.01	68,0.0054)0.313	-0.0113(-0.02	86,0.0059)0.196
Subgroup analysis stratified by age				
18-45	0.0001(-0.00	37,0.0039)0.957	-0.0014(-0.00	71,0.0043)0.625
45-65	-0.0037(-0.00	88,0.0014)0.156	-0.0073(-0.01	45,-0.0001)0.047
65-80	-0.0072(-0.01	62.0.0018)0.119	-0.0154(-0.02	820.0026)0.018

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

206

Results of the multiple regression analysis of Ward's triangle region revealed that 207

stratified by gender, female Ward's triangle BMD decreased while chloroform levels 208

209	increased and that female Ward's triangle BMC was negatively correlated with
210	chloroform. According to the results stratified by race, blood chloroform concentration
211	was negatively correlated with BMD/BMC except for Hispanic white subjects ( $\beta$ -
212	0.0124; 95%CI -0.0224, -0.0024; P<0.05); (β -0.0136; 95% CI -0.0244, -0.0027;
213	P<0.05). Additionally, although BMC was not statistically significant, chloroform
214	concentrations were correlated with BMD in Mexican-American, Other Hispanic, Non-
215	Hispanic Black and Other Race-Including Multi-Racial participants. The results
216	stratified by age revealed no statistically significant association between chloroform
217	concentrations and BMD and BMC at all femoral sites in all age groups
218	Female L4 BMC decreased with increasing blood chloroform in the spinal region
218 219	Female L4 BMC decreased with increasing blood chloroform in the spinal region following stratification by sex ( $\beta$ -0.009; 95% CI -0.0149, -0.0022; P<0.01). When
218 219 220	Female L4 BMC decreased with increasing blood chloroform in the spinal region following stratification by sex ( $\beta$ -0.009; 95% CI -0.0149, -0.0022; P<0.01). When stratified by race, we discovered a significant correlation between Non-Hispanic White
<ul><li>218</li><li>219</li><li>220</li><li>221</li></ul>	Female L4 BMC decreased with increasing blood chloroform in the spinal region following stratification by sex ( $\beta$ -0.009; 95% CI -0.0149, -0.0022; P<0.01). When stratified by race, we discovered a significant correlation between Non-Hispanic White BMC and blood chloroform ( $\beta$ -0.0078; 95% CI -0.0152, -0.0005; P<0.05).
<ul><li>218</li><li>219</li><li>220</li><li>221</li><li>222</li></ul>	Female L4 BMC decreased with increasing blood chloroform in the spinal region following stratification by sex ( $\beta$ -0.009; 95% CI -0.0149, -0.0022; P<0.01). When stratified by race, we discovered a significant correlation between Non-Hispanic White BMC and blood chloroform ( $\beta$ -0.0078; 95% CI -0.0152, -0.0005; P<0.05). Additionally, there was a significant negative correlation between BMC and
<ul> <li>218</li> <li>219</li> <li>220</li> <li>221</li> <li>222</li> <li>223</li> </ul>	Female L4 BMC decreased with increasing blood chloroform in the spinal region following stratification by sex ( $\beta$ -0.009; 95% CI -0.0149, -0.0022; P<0.01). When stratified by race, we discovered a significant correlation between Non-Hispanic White BMC and blood chloroform ( $\beta$ -0.0078; 95% CI -0.0152, -0.0005; P<0.05). Additionally, there was a significant negative correlation between BMC and chloroform in the 45-65 and 65-80 age groups when age was used as a stratification

225 0.0026; P< 0.05).

## 226 **Discussion**

Osteoporosis is a degenerative bone disease that increases the risk of fracture [20]. With the aging population, osteoporosis is becoming a major public health concern worldwide [21,22]. The current era of rapid global economic development characterized by various industrial processes, including increased production of

automobiles, tobacco, cleaning products, building materials, and other household 231 products, has made VOCs more common in the human environment [23,24,25,26,27]. 232 Several studies have demonstrated that some VOCs, such as Perfluoro and 233 Polyfluoroalkyl Substances (PFAS), Urinary Polycyclic Aromatic Hydrocarbons 234 (UPAHs), trichlorophenol, and many other organics are negatively associated with 235 BMD/BMC levels at specific sites in the human body [28,29,30]. The safety of urban 236 centralized water supply largely relies on water disinfection as it kills pathogens and 237 prevents waterborne infectious diseases [31]. However, water Disinfection Byproducts 238 239 (DBPs) mostly contain certain VOCs. including chloroform, bromine. dibromochloromethane, and dichlorobromomethane, with chloroform presence being 240 exceptionally high in these DBPs [32]. A survey specifically focused on chloroform 241 242 was conducted in China to evaluate the health risks associated with municipal water supply. It analyzed the distribution pattern and seasonal chloroform variation 243 characteristics in the municipal water supply in Xi'an and the average daily chloroform 244 245 exposure dose. According to the results, the average daily exposure dose of chloroform in the Xi'an municipal water supply was 7.39\*10^-4 mg/(kg\*d), with drinking water 246 consumption as the leading source for the non-carcinogenic risk of chloroform [33]. 247 Another survey found that the carcinogenic risk of ten contaminants in city drinking 248 water, including chloroform, exceeded the acceptable level [34]. All these studies 249 indicate that chloroform could potentially harm human health, but no conclusive study 250 has proven the dangers of chloroform exposure to public safety. Although some studies 251 have associated chloroform co-exposure with bone health indicators [15], no link with 252

BMD has been reported. In our study, we hypothesize that there could be a connection 253 between blood chloroform and BMD/BMC. After adjusting for confounders, we 254 discovered a negative correlation between BMD/BMC and blood chloroform in L3 255 BMC and L4 BMD/BMC. Our analysis revealed a negative association between 256 chloroform and femoral neck BMD in participants aged 65-80 years and Non-Hispanic 257 White subjects, as well as Ward's triangle BMD in women and Non-Hispanic White 258 subjects. For BMC, a negative correlation was found between blood chloroform and 259 femoral neck BMC, Non-Hispanic White and Other Race-Including Multi-Racial 260 subjects femoral neck BMC, female Ward's triangular BMC, Ward's Triangular BMC 261 of female Non-Hispanic White and 65-80 years old subjects, Female L4 and Non-262 Hispanic White Subjects BMC, and L4 BMC of 45-65 years and 65-80 years old 263 264 subjects.

Multiple linear regression analysis and analysis within the Asian group revealed 265 the relationship between blood chloroform and BMD/BMC in most areas of the femur 266 and spine before adjusting for confounding factors. However, after adjusting for 267 confounding variables, it was discovered that the correlation between blood chloroform 268 and femoral BMD/BMC was not as strong. This finding implies that the relationship 269 between blood chloroform and femoral BMD/BMC is largely influenced by age, gender, 270 and race. On the one hand, this phenomenon may be attributed to femur and lumbar 271 spine structures, which theoretically have the most substantial BMD changes in 272 postmenopausal women with a higher proportion of cancellous bone [35, 36, 37, and 273 38]. On the other hand, it could be attributed to the sample population's old age (48.8  $\pm$ 274

16.8 years), where hormonal drugs used by some older individuals exert a greater 275 influence on femoral BMD/BMC than on lumbar spine BMD/BMC, making blood 276 chloroform less likely to be associated with femoral BMD/BMC [39]. Furthermore, 277 after adjusting for relevant covariates, stratified analysis by age, sex, and race revealed 278 that chloroform concentration was negatively correlated with BMC at most sites. Blood 279 chloroform concentration at L4 was significantly negatively correlated with BMC in 280 women in the subgroup analysis. Contrastingly, no correlation between chloroform 281 concentration and femoral or spinal BMC was observed in men, implying that blood 282 283 chloroform levels may have some predictive value for bone mass in women. This phenomenon may be attributed to the sample population's older age  $(48.8 \pm 16.8 \text{ years})$ 284 and the substantial decline in sex hormone levels in postmenopausal women resulting 285 286 in lower femoral BMD quantity. Men, on the other hand, showed no such specific changes. We hypothesized that the varying sex hormone levels might influence the 287 femoral neck, Ward's triangle, or L4 BMC differently. Furthermore, the association 288 between blood chloroform and femoral and spinal BMC was closer than that of BMD, 289 which may be explained by the significant variations in the bone area resulting from 290 individual differences. 291

Both BMD and BMC have been shown by studies to be significant osteoporosis indicators and to play a critical role in osteoporotic fracture development [40]. Our study revealed a negative correlation between blood chloroform in some spine regions and BMD/BMC. Chloroform is used as a solvent to soften material during endodontic treatment, and case studies revealed that during the patients' endodontic retreatment

visit, chloroform was extruded through the perforation into the periodontal ligament 297 space, resulting in necrosis of the tooth-supporting bone [41]. Our findings on the 298 negative effect of chloroform on bone loss are consistent with another research which 299 discovered that organochlorine contaminants-exposure could impact fertility, the 300 menstrual cycle, and other aspects of the human reproductive system [42,43]. In a 301 pharmaceutical company, female personnel exposed to a mixture of organic solvents 302 (including chloroform) exhibited higher Thyroid-Stimulating Hormone (TSH) levels 303 than the non-exposed group, with a significant correlation between chloroform and 304 305 TSH levels [44]. According to some clinical studies, a positive correlation exists between TSH and femoral and spinal BMD in early postmenopausal women [45]. 306 Consequently, we speculate that chloroform may have a positive association with 307 308 BMD/BMC mediated by hormones in vivo, and this hypothesis is supported by the "V"shaped correlation between chloroform, and BMD/BMC discovered in our study (Fig2-309 3). Additionally, we hope to find the link between chloroform and bone metabolism 310 through preliminary data analysis and further basic research. In this regard, our group 311 has already started collecting environmental exposure samples and establishing a 312 sample bank. (Fig2-3:Restricted cubic spline plots between chloroform and femoral 313 neck BMC and chloroform and L4 BMC) 314

With this cross-sectional research, we plan to further explore the effect of chloroform exposure on BMD/BMC. Herein, we used raw data on blood chloroform and femoral and spinal BMD/BMC from adults selected from NHANES in 2009-2010, 2013-2014, and 2017-2020 to perform a Restricted Cubic Splines (RCS) analysis of the

relationship between chloroform and BMD/BMC. The non-linear connection between 319 blood chloroform and spinal BMD/BMC revealed a "V" shaped correlation and a 320 321 statistically significant association between chloroform levels within the 0-0.02 ng/ml range and spinal BMD/BMC (Figure2-3). According to the literature review in some 322 studies, chloroform harms BMD/BMC. Contrastingly, some studies suggest that 323 chloroform may have a positive association with BMD/BMC. However, no specific 324 reference in the literature demonstrates a clear connection between chloroform and 325 BMD/BMC; thus, more research is required to determine the optimal level of 326 327 chloroform exposure in relation to BMD/BMC levels. The above findings imply that exposure to VOCs such as chloroform remains a major public health concern. 328 Disinfection byproducts are ubiquitous, and people (particularly older adults) with 329 330 prolonged exposure to the chloroform from these products must be especially aware of their long-term risks. 331

### 332 Limitation

Our study had several limitations. First, the data used in this investigation was obtained 333 from NHANES, and therefore it was difficult to establish the exact timing between 334 chloroform exposure and changes in BMD. Consequently, we could only develop 335 correlations but not causality at this point. More research through prospective studies 336 is therefore required to investigate this further. Second, our data on subjects were 337 primarily from a single time point, making it difficult to determine the association 338 between chloroform and BMD/BMC over time, potentially leading to bias in 339 classifying specific populations. Third, some data were from self-reported 340

questionnaires, which may have resulted in recall or misclassification bias. Fourth, missing whole-body skeletal BMD/BMC data impeded a comprehensive examination of the chloroform and BMD/BMC correlation. Finally, the residual confounding problem persisted despite employing multivariate adjustment techniques. We are developing a cohort of VOC exposure (including chloroform) in our city and expect that more convincing evidence elucidating the link between chloroform and BMD/BMC will soon be available.

## 348 Conclusion

After adjustment for confounders, we established a "V" shaped correlation between blood chloroform and femoral spine BMD/ BMC, with a negative correlation at 0-0.02 ng/ml (p<0.05), especially for L4 BMC. Our research provides epidemiological evidence for further investigation into the correlation between chloroform and BMD/ BMC.

### 354 Acknowledgements

This thesis would not have been possible without the consistent and valuable reference materials that I received from my supervisor whose insightful guidance and enthusiastic encouragement in the course of my shaping this thesis definitely gains my deepest gratitude.

### 359 **References**

Lane JM, Russell L, Khan SN. Osteoporosis. Clin Orthop Relat Res. 2000
 Mar;(372):139-50.10. doi:1097/00003086-200003000-00016

362	2.	Farrah Z, Jawad AS. Optimising the management of osteoporosis. Clinical
363		medicine (London, England). 2020 Sep;20(5): e196-e201. doi:
364		10.7861/clinmed.2020-0131
365	3.	Zhang R, Huang Q, Su G, Wei M, Cui Y, Zhou H, Song W, Di D, Liu J, Wang Q.
366		Association between multiple vitamins and bone mineral density: a cross-sectional
367		and population-based research in the NHANES from 2005 to 2006. Population-
368		based research in the NHANES from 2005 to 2006. BMC Musculoskelet Disord.
369		2023 Feb 10;24(1):113. doi: 10.1186/s12891-023-06202-6
370	4.	Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The
371		epidemiology of osteoporosis. Br Med Bull. 2020 May 15;133(1):105-117.
372		doi:10.1093/bmb/ldaa005
373	5.	Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley
374		JA, Bauer DC, Black DM; FNIH Bone Quality Project. Change in Bone Density
375		and Reduction in Fracture Risk: A Meta-Regression of Published Trials. J Bone
376		Miner Res. 2019 Apr;34(4):632-642. doi:10.1002/jbmr.3641
377	6.	Levin VA, Jiang X, Kagan R. Estrogen Therapy for osteoporosis in the modern
378		era. Osteoporos Int. 2018;29(5):1049-1055. doi: 10.1007/s00198-018-4414-z
379	7.	Chen LR, Hou PH, Chen KH. Nutritional support and physical modalities for
380		people with osteoporosis: current opinion. Nutrients. 2019;11(12): 15. doi:
381		10.3390/nu11122848
382	8.	Li Adela Jing, Pal Vineet Kumar, and Kannan Kurunthachalam. A review of
383		environmental occurrence, toxicity, biotransformation and biomonitoring of

volatile organic compounds." 3.(2021):91-116.

- McGraw KE, Riggs DW, Rai S, Navas-Acien A, Xie Z, Lorkiewicz P, et al.
   Exposure to volatile organic compounds acrolein, 1,3-butanadiene, and
   crotonaldehyde is associated with vascular dysfunction. environ res. (2021)
- 388 196:110903. doi:10.1016/j. envres.2021.110903
- 10. Wei C, Chen Y, Yang Y, Ni D, Huang Y, Wang M, Yang X, Chen Z. Assessing
- 390 Volatile Organic Compounds Exposure and Prostate-specific Antigen: National
- Health and Nutrition Examination Survey, 2001-2010. Front Public Health. 2022
- 392 Jul 29; 10: 957069. doi:10.3389/fpubh.2022.957069
- 11. National Toxicology Program. NTP toxicology and carcinogenesis studies of
   methyl bromide (CAS: 74-83-9) in B6C3F1 mice (inhalation studies). Natl Toxicol
   Program Tech Rep Ser. 1992 Mar; 385: 1-212.
- 396 12. Smith JT, Schneider AD, Katchko KM, Yun C, Hsu EL. Environmental factors
- impacting bone-relevant chemokines. Front Endocrinol (Lausanne). 2017 Feb 14;
- 398 8: 22. doi: 10.3389/fendo.2017.00022
- 13. Lehmann I, Roder-Stolinski C, Nieber K, Fischader G. In vitro models for the
  assessment of inflammatory and immuno-modulatory effects of the volatile
  organic compound chlorobenzene. *Exp Toxicol Pathol* (2008) 60(2–3):185–93. doi:
- 402 10.1016/j.etp.2008.01.009
- 403 14. Fischader G, Roder-Stolinski C, Wichmann G, Nieber K, Lehmann I. Release of
- 404 MCP-1 and IL-8 from lung epithelial cells exposed to volatile organic compounds.
- 405 Toxicol In Vitro (2008) 22(2):359–66. doi: 10.1016/j.tiv.2007.09.015

406	15.	Zhou HL, Su GH, Zhang RY, Di DS, Wang Q. Association of volatile organic
407		compounds co-exposure with bone health indicators and potential mediators.
408		Chemosphere.         2022         Dec;308(Pt         1):136208.         doi:
409		10.1016/j.chemosphere.2022.136208
410	16.	Batterman S, Su FC, Li S, Mukherjee B, Jia C; HEI Health Review Committee.
411		Personal exposure to mixtures of volatile organic compounds: modeling and res
412		health eff Inst. 2014 Jun;(181):3-63.
413	17.	Toxicity of Chloroform. Prescrire Int. 1998 Oct;7(37):149.
414	18.	Cui Y, Zhou HL, Wei MH, Song WJ, Di DS, Zhang RY, et al. Multiple vitamin
415		co-exposure and mortality risk: a prospective research. Clin Nutr. 2022; 41(2): 337
416		-347. doi: 10.1016/j.clnu.2021.12.010
417	19.	Lee S, Ko K, Shin S, Park HS, Hong N, Rhee Y. Adipopenia is associated with
418		osteoporosis in community-dwelling non-underweight adults independent of
419		sarcopenia. Arch Osteoporos. 2023 Mar 22;18(1): 44. doi:10.1007/s11657-023-
420		01233-х
421	20.	Song S, Guo Y, Yang Y, Fu D. Advances in pathogenesis and therapeutic strategies
422		for osteoporosis. <i>Pharmacol Ther</i> . (2022) 237:108168. doi:
423		10.1016/j.pharmthera.2022.108168
424	21.	Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al.
425		Osteoporosis in the European Union: medical management, epidemiology and
426		economic burden. A report prepared in collaboration with the international

427 osteoporosis foundation (IOF) and the European Federation of Pharmaceutical

428	Industry	Associations	(EFPIA).	Arch	Osteoporos.	(2013)	8:136.	doi:
429	10.1007/s	s11657-013-013	36-1					

- 22. Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, et
  al. The global prevalence of osteoporosis in the world: a comprehensive systematic
  review and meta-analysis. *J Orthop Surg* Res. 2021 Oct 17;16(1):609. doi:
  10.1186/s13018-021-02772-0
- 434 23. Konkle SL, Zierold KM, Taylor KC, Riggs DW, Bhatnagar A. National secular
  435 trends in ambient air volatile organic compound levels and biomarkers of exposure
  436 in the United States. Environ Res. (2020) 182:108991. doi:10.1016/j.envres.
  437 2019.108991
- 438 24. Jain RB. Detection Rates, Trends in and factors affecting observed levels of439 selected volatile organic compounds in blood among us adolescents and adults.
- 440 Environ Toxicol Pharmacol.(2017) 56:21-8.doi:10.1016/j.etap.2017.08.031
- 441 25. Jain RB. Distributions of selected urinary metabolites of volatile organic
  442 compounds by age, gender, race/ethnicity, and smoking status in a representative
  443 sample of US adults. Environ Toxicol Pharmacol. (2015) 40: 471-9.
  444 doi:10.1016/j.etap.2015.07.018
- Liu B, Jia C. Effects of exposure to mixed volatile organic compounds on the
   neurobehavioral test performance in a cross-sectional research of US adults. Int J
- Environ Health Res. (2015) 25: 349-63. doi:10.1080/09603123.2014.945514
- 448 27. Su FC, Jia C, Batterman S. Extreme value analyses of VOC exposures and risks: a
  449 comparison of riopa and NHANES datasets. atmospheric environ. (2012) 62:97.

- 450 106. doi: 10.1016/j.atmosenv. 2012.06.038
- 451 28. Yan Z, Xiong X, Tao J, Wang S. Association of bone mineral density with
- trichlorophenol: a population-based research. BMC musculoskelet disord. 2023
- 453 Mar 17. 24(1): 202. doi:10.1186/s12891-023-06323-y
- 454 29. Kirk AB, DeStefano A, Martin A, Kirk KC, Martin CF. A new interpretation of
- 455 relative importance on an analysis of per and polyfluorinated alkyl substances
- 456 (PFAS) exposures on bone mineral density. Int J Environ Res Public Health. 2023
- 457 Mar 3; 20 (5): 4539. doi:10.3390/ijerph20054539
- 458 30. Yang R, Chen Z, Hu Y. Associations of urinary polycyclic aromatic hydrocarbons
- 459 with bone mineral density at specific body sites in U.S. Adults, National Health
- and Nutrition Examination Survey 2001 to 2004. Endocr Pract. 2022 Sep; 28(9):
- 461 867-874.10.1016/j.eprac.2022.06.008
- 462 31. Yang KD. Environmental hygiene (M). Beijing: people's medical publishing house,
  463 2017.
- 464 32. Xu H, Cai J. Determination and risk assessment of disinfection by- products in
  465 drinking water of S city(J). Water & Wastewater Engineering, 2020,56(9):37-40.
- 466 33. Zhao GP, Zou KT, Xu Q, Liu RX, Luo XH, Guan R. Distribution characteristics
- and multi pathways health risk assessment of trichloromethane in municipal water
  of Xi'an.Modern Preventive Medicine(J). 2023,50(4):611-617.
- 469 34. Han JY,Ye BX,Zhang L. Health Risk Assessment of 10 pollutants in a city's
  470 drinking water.Journal of environmental hygiene Jun(J).2019,9(3):203-209.
- 471 35. Wang C, Zhu Y, Long H, Ou M, Zhao S. Connection between blood manganese

472		and bone mineral density and bone mineral content in adults: a population-based
473		cross-sectional research. PLoS One. 2022 Oct 21; 17(10): e0276551.
474		doi:10.1371/journal.pone.0276551
475	36.	Mosekilde L, Danielsen CC, Gasser J. The effect on vertebral bone mass and
476		strength of long term treatment with antiresorptive agents (estrogen and calcitonin),
477		human parathyroid hormone-(1-38), and combination therapy, assessed in aged
478		ovariectomized rats. Endocrinology. 1994 May;134(5):2126-34. doi:
479		10.1210/endo.134.5.8156913.
480	37.	Liu J, Wang W, Tong QJ, et al. A comparative research of dual-energy X-ray bone
481		densitometry (DXA) and A comparative research of bone density measurement by
482		dual-energy X-ray bone densitometry (DXA) and quantitative CT (QCT)(J).
483		Journal of Clinical Radiology.2007, 26(5): 504- 507.
484	38.	Yamauchi H, Kushida K, Yamazaki K, et al. Assessment of spine bone mineral
485		density in ovariectomized rats using DXA(J). J Bone Miner Res, 1995, 10(7):
486		1033- 1036. doi: 10.1002/jbmr.5650100707
487	39.	Yin X, Zhao S, Xiang N, Chen J, Xu J, Zhang Y. Efficacy of Bushen Jiangu therapy
488		in the treatment of glucocorticoid-induced osteoporosis: A systematic review and
489		meta-analysis of randomized controlled trials. Medicine (Baltimore). 2023 Mar
490		17;102(11): e33278. doi: 10.1097/MD.00000000033278
491	40.	Deng HW, Xu FH, Davies KM, Heaney R, Recker RR. Differences in Bone
492		Mineral Density, Bone Mineral Content, and Bone Areal Size in Fracturing and
493		Non-fracturing Women, and Their Interconnections at the Spine and Hip.

494		Fracturing Women, and Their Interconnections at the Spine and Hip. Journal of
495		bone and mineral metabolism. 2002; 20(6): 358-66.doi:10.1007/s007740200052
496	41.	Mohammadzadeh Akhlaghi N, Baradaran Mohajeri L, Fazlyab M. Tissue Necrosis
497		due to Chloroform: a Case Report. Iran Endod J. 2013 Fall;8(4):208-9.
498	42.	Bonde JP, Toft G, Rylander L, Rignell-Hydbom A, Giwercman A, Spano M,
499		Manicardi GC, Bizzaro D, Ludwicki JK, Zvyezday V, Bonefeld-Jørgensen EC,
500		Pedersen HS, Jönsson BA, Thulstrup AM; INUENDO. Fertility and markers of
501		male reproductive function in Inuit and European populations spanning large
502		contrasts in blood levels of persistent organochlorines. Environ Health Perspect.
503		2008 Mar;116(3):269-77. doi: 10.1289/ehp.10700
504	43.	Figa-Talamanca I. Occupational risk factors and reproductive health of women.
505		Occup Med (Lond) 2006; 56: 521–531. doi: 10.1093/occmed/kql114
506	44.	Hassani S, Namvar M, Ghoreishvandi M, Attarchi M, Golabadi M, Seyedmehdi
507		SM, Khodarahmian M. Menstrual disturbances and hormonal changes in women
508		workers exposed to a mixture of organic solvents in a pharmaceutical company.
509		Med J Islam Repub Iran. 2014 Dec 27; 28:156.
510	45.	Begić A, Begić A, Arnautović-Halimić A. Influence of thyroid hormones on bone
511		density. Med Glas (Zenica). 2020 Feb 1;17(1):35-40. doi: 10.17392/1056-20
512	Su	pporting information
513	<b>S1</b>	Table Related demographic characteristics of participants included in

513

NHANES from 2009 to 2010 and 2013 to 2014 and 2017-2020. Means with 514

standard deviation (SD) were used for continuous characteristic variables and 515

- 516 categorical variables were expressed as frequencies. Differences in categorical
- 517 variables between exposed groups were analyzed by Kruskal Wallis test or Mann
- 518 Whitney test. Spearman correlation analysis was used to analyze the differences of
- 519 continuous variables between groups.
- 520 (EXCEL)
- 521 S2 Table Blood chloroform and area, BMC, and BMD based on chloroform
- 522 tristimulus. Data are expressed as means (standard deviation, SD). BMC, bone mineral
- 523 content, BMD, bone mineral density, Area (cm2), BMC (g), BMD (g/cm2). (EXCEL)



# Figure



Figure



Figure